Evidence map›Paper›PMID 34622157›Full record

ArticleiScience2021

MTDH associates with m6A RNA methylation and predicts cancer response for immune checkpoint treatment.

Fen Zhang, Huimei Huang, Yuexiang Qin, Changhan Chen, Li She, Juncheng Wang, Donghai Huang, Qinglai Tang, Yong Liu, Gangcai Zhu and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. The Role of Zuo Jin Wan in Modulating the Tumor Microenvironment of Colorectal Cancer.Combinatorial chemistry & high throughput screening · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Fen ZhangDepartment of Emergency Medicine, Changsha Central Hospital, University of South China, Changsha 410001, China.
Huimei HuangDepartment of Otolaryngology-Head and Neck Surgery, Second Xiangya Hospital, Central South University, Changsha 410010, China.
Yuexiang QinHealth Management Center, Third Xiangya Hospital, Central South University, Changsha 410011, China.
Changhan ChenDepartment of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Li SheDepartment of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Juncheng WangDepartment of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Donghai HuangDepartment of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Qinglai TangDepartment of Otolaryngology-Head and Neck Surgery, Second Xiangya Hospital, Central South University, Changsha 410010, China.
Yong LiuDepartment of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Gangcai ZhuDepartment of Otolaryngology-Head and Neck Surgery, Second Xiangya Hospital, Central South University, Changsha 410010, China.
Xin ZhangDepartment of Otolaryngology-Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Central South University · CNChangsha Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint blockade (ICB) persistently provides a prognosis improvement but only in a small fraction of patients with cancer due to immunotherapy resistance induced by the consecutive activated oncogenic pathways, including MAPK, Akt, and WNT pathway partially driven by Metadherin (MTDH). However, there is no study to investigate the potential role and mechanisms of MTDH in ICB-treated cancers. Here, we systematically explored the cohorts from The Cancer Genome Atlas (TCGA) and independent cancer cohorts. Elevated MTDH expression was founded to associate with a worse overall survival and poorer immune response in patients with cancer. Dysregulated tumor-infiltrating immune cells and inhibitory immune checkpoint expression were correlated with MTDH expression. Furthermore, the mutual interactions between epithelial-to-mesenchymal-transition, m6A-RNA-methylation, and MTDH may illustrate the potential mechanisms of MTDH resistant to ICB treatment. Although more designed experiments and trials are needed in the future, targeting MTDH may help to overcome immunotherapy resistance in a wide range of cancers.

Indexed as

Biological sciencesExpression studyMolecular biology

Identifiers

PMID34622157
PMCPMC8479698
OpenAlexW3200763057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.